Transform Wealth LLC Acquires 1,141 Shares of CVS Health Co. (NYSE:CVS)

Transform Wealth LLC grew its position in shares of CVS Health Co. (NYSE:CVSGet Rating) by 1.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 107,097 shares of the pharmacy operator’s stock after purchasing an additional 1,141 shares during the period. CVS Health comprises about 1.5% of Transform Wealth LLC’s holdings, making the stock its 15th largest holding. Transform Wealth LLC’s holdings in CVS Health were worth $9,924,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in CVS Health by 2.4% during the first quarter. Vanguard Group Inc. now owns 111,865,662 shares of the pharmacy operator’s stock worth $11,321,923,000 after purchasing an additional 2,628,740 shares during the last quarter. State Street Corp increased its holdings in CVS Health by 4.3% during the 1st quarter. State Street Corp now owns 59,261,304 shares of the pharmacy operator’s stock valued at $5,997,837,000 after purchasing an additional 2,450,990 shares during the period. Capital World Investors grew its holdings in shares of CVS Health by 17.0% during the 1st quarter. Capital World Investors now owns 58,633,421 shares of the pharmacy operator’s stock worth $5,934,465,000 after acquiring an additional 8,531,311 shares during the period. Capital International Investors grew its holdings in shares of CVS Health by 1.1% during the 1st quarter. Capital International Investors now owns 28,139,498 shares of the pharmacy operator’s stock worth $2,848,157,000 after acquiring an additional 318,021 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in shares of CVS Health by 9.5% during the 1st quarter. Bank of New York Mellon Corp now owns 16,028,628 shares of the pharmacy operator’s stock worth $1,622,257,000 after acquiring an additional 1,385,322 shares during the period. Institutional investors own 77.64% of the company’s stock.

CVS Health Price Performance

CVS stock traded down $2.36 during trading on Friday, reaching $97.47. The company’s stock had a trading volume of 183,225 shares, compared to its average volume of 4,398,985. The company’s fifty day moving average is $100.14 and its 200-day moving average is $99.28. CVS Health Co. has a 1 year low of $81.78 and a 1 year high of $111.25. The company has a market capitalization of $127.96 billion, a P/E ratio of 15.91, a price-to-earnings-growth ratio of 1.52 and a beta of 0.73. The company has a quick ratio of 0.65, a current ratio of 0.91 and a debt-to-equity ratio of 0.67.

CVS Health (NYSE:CVSGet Rating) last released its quarterly earnings data on Wednesday, August 3rd. The pharmacy operator reported $2.40 EPS for the quarter, beating the consensus estimate of $2.16 by $0.24. CVS Health had a net margin of 2.65% and a return on equity of 15.19%. The business had revenue of $80.64 billion during the quarter, compared to the consensus estimate of $76.38 billion. During the same quarter in the prior year, the firm earned $2.42 EPS. The business’s revenue was up 11.0% on a year-over-year basis. On average, research analysts expect that CVS Health Co. will post 8.53 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 1st. Shareholders of record on Friday, October 21st will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 2.26%. The ex-dividend date is Thursday, October 20th. CVS Health’s dividend payout ratio (DPR) is presently 35.77%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on CVS shares. Sanford C. Bernstein cut CVS Health from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $122.00 to $112.00 in a research report on Thursday, May 26th. Credit Suisse Group increased their price target on CVS Health from $113.00 to $117.00 and gave the company an “outperform” rating in a report on Monday, August 8th. Tigress Financial increased their price target on CVS Health from $125.00 to $130.00 in a report on Wednesday, August 17th. UBS Group increased their price target on CVS Health from $118.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, August 4th. Finally, Mizuho increased their price target on CVS Health from $115.00 to $120.00 and gave the company a “buy” rating in a report on Monday, August 15th. Four equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $117.59.

Insider Buying and Selling at CVS Health

In related news, EVP Alan Lotvin sold 22,541 shares of the stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $104.00, for a total value of $2,344,264.00. Following the completion of the transaction, the executive vice president now owns 109,183 shares of the company’s stock, valued at approximately $11,355,032. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other CVS Health news, EVP Alan Lotvin sold 22,541 shares of the firm’s stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $104.00, for a total value of $2,344,264.00. Following the completion of the sale, the executive vice president now owns 109,183 shares of the company’s stock, valued at $11,355,032. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Thomas M. Moriarty sold 138,654 shares of the firm’s stock in a transaction dated Tuesday, June 28th. The stock was sold at an average price of $95.00, for a total transaction of $13,172,130.00. Following the completion of the sale, the executive vice president now directly owns 626,273 shares of the company’s stock, valued at approximately $59,495,935. The disclosure for this sale can be found here. Insiders own 0.69% of the company’s stock.

About CVS Health

(Get Rating)

CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.

Featured Stories

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVSGet Rating).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.